The study hypothesis was an integrated analysis of proteomics and genomics of primary muscle-invasive bladder cancer, and patient-derived xenografts will define mechanisms for chemotherapy resistance and identify candidate driver genes leading to the identification of specific targeted therapies for those resistant to the current standard of care. The clinical and banking workflow needed includes post-referral restaging and post-chemotherapy restaging prior to radical cystectomy. This is critical in order to place the tissue in a tumor bank for subsequent analysis. The target for the study is n=80 which has almost finished accrual. Requirements include minimum >50% tumor cellularity, urothelial and variant histology.
Dr. Lerner presented promising preliminary results (not to be made publicly available). He discussed the multiplexed inhibitor bead Kinome Pull-down (KIP) profiling which the mixture of 9 kinase inhibitor beads designed to isolate and enrich the kinases with the most activity. The Clinical Proteomic Tumor Analysis Consortium (CPTAC) has developed for proteomics. In conclusion, proteomic profiling identifies clusters with similar protein kinase expression patterns. KIP assays offer high throughput mass spectrometry to identify druggable kinases and candidate kinase inhibitors. CPTAC for bladder cancer is expected to be developed in 2020-2021.
Presented by: Seth P. Lerner, MD, FACS, Beth and Dave Swalm Chair in Urologic Oncology, Director of Urologic Oncology, Director of the Multidisciplinary Bladder Cancer Program, Baylor College of Medicine, Houston, Texas
Written by: Stephen B. Williams, MD, Medical Director for High Value Care; Chief of Urology, Associate Professor, Director of Urologic Oncology, Director Urologic Research, The University of Texas Medical Branch at Galveston, TX and Ashish M. Kamat, MD, Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 2019 Bladder Cancer Advocacy Network (BCAN) Think Tank August 8-10, 2019 - the Capital Hilton, Washington, DC, USA
Presented by: Seth P. Lerner, MD, FACS, Beth and Dave Swalm Chair in Urologic Oncology, Director of Urologic Oncology, Director of the Multidisciplinary Bladder Cancer Program, Baylor College of Medicine, Houston, Texas
Written by: Stephen B. Williams, MD, Medical Director for High Value Care; Chief of Urology, Associate Professor, Director of Urologic Oncology, Director Urologic Research, The University of Texas Medical Branch at Galveston, TX and Ashish M. Kamat, MD, Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 2019 Bladder Cancer Advocacy Network (BCAN) Think Tank August 8-10, 2019 - the Capital Hilton, Washington, DC, USA